The Novo-backed surgical implant provider floated at the top of its range and increased the number of shares in the offering.

Existing investor Biocon bought more shares in a $65.4m offering that involved the immuno-inflammatory disorder drug developer floating at the bottom of its range.

Banks have reportedly suggested a $120bn valuation for Uber's IPO, while Lyft has chosen JP Morgan to lead an offering that could value it at more than $15bn.

Legend Holdings, Eli Lilly, Ping An, China Life and Taikang Insurance are in line for exits as Innovent Biologics gears up for an initial public offering sized at $400m to $500m.

The underwriters took up the option to buy another 2.7 million shares after the Pfizer and Gilead-backed oncology therapy developer's shares leapt substantially post-IPO.

Anaplan has raised close to $264m in its flotation on the New York Stock Exchange that provided exits for Salesforce and Workday.

The Pfizer and Gilead-backed immuno-oncology therapy developer, which had raised $300m in an April series A round, floated at the top of its range.

The synthetic DNA technology developer, which counts Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux, has filed to raise up to $86.3m.

GSK is the second largest shareholder of gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.

The UCL Technology Fund is in line for an exit from gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.